We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-11.64%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
-$306M
Cap. Flow
-$59.1M
Cap. Flow %
-5.47%
Top 10 Hldgs %
66.39%
Holding
80
New
21
Increased
8
Reduced
13
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
2
MRK icon
Merck
MRK
+$18.4M
3
ALGN icon
Align Technology
ALGN
+$11.1M
4
HRTX icon
Heron Therapeutics
HRTX
+$8.1M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.87M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
FATE icon
Fate Therapeutics
FATE
+$15.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
CALL
Gilead Sciences
GILD
$166B
$7.48M 0.69%
+100,000
New +$6.91M
KALA icon
27
PUT
KALA BIO
KALA
$12.1M
$6.48M 0.6%
+295
New +$4.71M
KDMN
28
DELISTED
Kadmon Holdings, Inc.
KDMN
$6.39M 0.59%
1,526,178
-842,780
-36% -$3.63M
CHMA
29
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.95M 0.55%
1,630,221
– –
MIRM icon
30
Mirum Pharmaceuticals
MIRM
$6.86B
$5.86M 0.54%
+418,589
New +$6.87M
HRTX icon
31
Heron Therapeutics
HRTX
$90.9M
$5.65M 0.52%
481,608
+431,108
+854% +$8.1M
PBYI icon
32
Puma Biotechnology
PBYI
$393M
$5.38M 0.5%
+638,026
New +$6.2M
FOLD
33
DELISTED
Amicus Therapeutics
FOLD
$4.86M 0.45%
525,530
+50,200
+11% +$477K
ITRM
34
DELISTED
Iterum Therapeutics
ITRM
$4.68M 0.43%
115,101
– –
IOVA icon
35
CALL
Iovance Biotherapeutics
IOVA
$2.15B
$4.49M 0.42%
+150,000
New +$3.98M
AXSM icon
36
Axsome Therapeutics
AXSM
$12.2B
$4.3M 0.4%
+73,163
New +$5.96M
ABBV icon
37
AbbVie
ABBV
$468B
$3.81M 0.35%
+50,000
New +$4.26M
BPMC
38
DELISTED
Blueprint Medicines
BPMC
$3.69M 0.34%
+63,100
New +$4.06M
CALA
39
DELISTED
Calithera Biosciences, Inc
CALA
$3.64M 0.34%
40,950
-31,991
-44% -$3.81M
QTTB icon
40
Q32 Bio
QTTB
$449M
$3.58M 0.33%
12,815
+9,237
+258% +$2.83M
AGTC
41
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.48M 0.32%
+1,062,615
New +$5.6M
AKRO
42
PUT
DELISTED
Akero Therapeutics
AKRO
$3.18M 0.29%
+150,000
New +$3.22M
AKRO
43
DELISTED
Akero Therapeutics
AKRO
$3.15M 0.29%
+148,415
New +$3.18M
ETTX
44
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$3.12M 0.29%
1,180,178
– –
OTIC
45
DELISTED
Otonomy, Inc.
OTIC
$2.99M 0.28%
1,515,629
– –
ALNY icon
46
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$2.95M 0.27%
27,100
-72,900
-73% -$8.41M
TGTX icon
47
TG Therapeutics
TGTX
$8.52B
$2.71M 0.25%
275,305
-535,987
-66% -$6.77M
CCXI
48
DELISTED
ChemoCentryx, Inc.
CCXI
$2.68M 0.25%
66,695
-310,249
-82% -$13.2M
RIGL icon
49
Rigel Pharmaceuticals
RIGL
$689M
$2.26M 0.21%
+144,632
New +$3.08M
PTCT icon
50
CALL
PTC Therapeutics
PTCT
$6.09B
$2.23M 0.21%
+50,000
New +$2.52M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2020 Portfolio in Review

As of Q1 2020, Sofinnova Investments held 80 positions worth $1.08B, down 22% from $1.39B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments withdrew a net $59.1M in Q1 2020, closing 16 positions and reducing 13 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Alexion Pharmaceuticals worth $27.6M.

  • Sofinnova Investments's largest Q1 2020 buy was Alexion Pharmaceuticals: 307,300 shares worth $27.6M.
  • Sofinnova Investments added most to Merck in Q1 2020, an estimated $18.4M increase.
  • Sofinnova Investments's biggest Q1 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.4M.
  • Sofinnova Investments fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $18.8M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $1.08B portfolio in Q1 2020.
  • Sofinnova Investments opened 21 new positions and closed 16 in Q1 2020.
  • Sofinnova Investments's portfolio value fell 22% quarter-over-quarter to $1.08B.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.